Intensified therapy with inhaled corticosteroids and long-acting b2-agonists at the onset of upper respiratory tract infection to prevent chronic obstructive pulmonary disease exacerbations a multicenter, randomized, double-blind, placebo-controlled trial
Stolz, D.; Hirsch, H. H.; Schilter, D.et al.
2018 • In American Journal of Respiratory and Critical Care Medicine, 197 (9), p. 1136-1146
Stolz, D.; Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, Basel, Switzerland, Department of Biomedicine, University of Basel, Basel, Switzerland, University of Basel, Basel, Switzerland
Hirsch, H. H.; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland, Department of Biomedicine, University of Basel, Basel, Switzerland, University of Basel, Basel, Switzerland, Transplantation and Clinical Virology, Department of Biomedicine, Basel, Switzerland
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Rakic, Janko
Boeck, L.; Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, Basel, Switzerland, Department of Biomedicine, University of Basel, Basel, Switzerland, University of Basel, Basel, Switzerland
Papakonstantinou, E.; Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, Basel, Switzerland, Department of Biomedicine, University of Basel, Basel, Switzerland, University of Basel, Basel, Switzerland
Schindler, C.; University of Basel, Basel, Switzerland, Swiss Tropical and Public Health Institute, Basel, Switzerland
Grize, L.; University of Basel, Basel, Switzerland, Swiss Tropical and Public Health Institute, Basel, Switzerland
Tamm, M.; Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, Basel, Switzerland, Department of Biomedicine, University of Basel, Basel, Switzerland, University of Basel, Basel, Switzerland
Language :
English
Title :
Intensified therapy with inhaled corticosteroids and long-acting b2-agonists at the onset of upper respiratory tract infection to prevent chronic obstructive pulmonary disease exacerbations a multicenter, randomized, double-blind, placebo-controlled trial
Publication date :
May 2018
Journal title :
American Journal of Respiratory and Critical Care Medicine
Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613–620.
Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117(Suppl. 2):5S–9S.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747–1757.
Hoyert D, Kung H, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005;53:1–48.
Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523–532.
Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144: 894–903.
Seemungal T, Sykes A; ICEAD Contributors. Recent advances in exacerbations of COPD. Thorax 2008;63:850–852.
Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 2005;26:846–852.
Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:245–251.
Proud D, Chow CW. Role of viral infections in asthma and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2006;35: 513–518.
Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 2008; 14:633–640.
Ritchie AI, Farne HA, Singanayagam A, Jackson DJ, Mallia P, Johnston SL. Pathogenesis of viral infection in exacerbations of airway disease. Ann Am Thorac Soc 2015;12:S115–S132.
MacNee W. Acute exacerbations of COPD. Swiss Med Wkly 2003;133: 247–257.
Greenberg SB. Viral respiratory infections in elderly patients and patients with chronic obstructive pulmonary disease. Am J Med 2002;112:28S–32S.
Djukanovic R, Gadola SD. Virus infection, asthma, and chronic obstructive pulmonary disease. N Engl J Med 2008;359:2062–2064.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.
Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641–647.
O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129–136.
Stolz D, Hirsch H, Schilter D, Louis R, Boeck L, Rakic J, et al. Intensified combination therapy with inhaled corticosteroids and long acting b2 agonists at the onset of URTI to prevent exacerbations of COPD: a randomized, placebo controlled study [abstract]. Am J Respir Crit Care Med 2017;195:A7708.
Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD 2005; 2:75–79.
Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012;40:1545–1554.
Cazzola M, Matera MG. Long-acting b(2) agonists as potential option in the treatment of acute exacerbations of COPD. Pulm Pharmacol Ther 2003;16:197–201.
Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002;165:698–703.
Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007;29:660–667.
Aaron SD, Vandemheen KL, Maltais F, Field SK, Sin DD, Bourbeau J, et al. TNFa antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax 2013;68:142–148.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary. Eur Respir J 2017;49:1700214. [Published erratum appears in Eur Respir J 49:1700214.]
Chronic obstructive pulmonary disease in over 16s: diagnosis and management [created June 2010; accessed 2018 Mar 28]. Available from: https://www.nice.org.uk/guidance/cg101.
Cazzola M. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19:79–89.
Bourbeau J, Sedeno MF, Metz K, Li PZ, Pinto L. Early COPD exacerbation treatment with combination of ICS and LABA for patients presenting with mild-to-moderate worsening of dyspnea. COPD 2016;13:439–447.
Santus P, Centanni S, Verga M, Di Marco F, Matera MG, Cazzola M. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med 2006;100:1277–1281.
Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al.; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371:1285–1294.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al.; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374: 2222–2234.
Izquierdo JL, Martín A, de Lucas P, Rodríguez-González-Moro JM, Almonacid C, Paravisini A. Misdiagnosis of patients receiving inhaled therapies in primary care. Int J Chron Obstruct Pulmon Dis 2010;5: 241–249.
Burgel PR, Deslée G, Jebrak G, Brinchault G, Caillaud D, Chanez P, et al.; Initiatives BPCO scientific committee. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J 2014;43:1201–1203.
Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912–919.
Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549–565.
Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al.; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602–615.
Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164: 1618–1623.
Johnston NW, Olsson M, Edsbäcker S, Gerhardsson de Verdier M, Gustafson P, McCrae C, et al. Colds as predictors of the onset and severity of COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2017;12:839–848.
Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946.
